Metastasis-suppressor genes: A review and perspective on an emerging field

Journal of the National Cancer Institute

Volumn 92, Issue 21, 2000, Pages 1717-1730

  Yoshida, Barbara A ^a   Sokoloff, Mitchell M ^a   Welch, Danny R ^b   Rinker Schaeffer, Carrie W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENETICS; CANCER GROWTH; CHROMOSOMAL LOCALIZATION; CHROMOSOME 17; CHROMOSOME 6; GENE CONTROL; GENETIC ANALYSIS; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0034329595     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.21.1717     Document Type: Review

References (160)

1. The role of cancer staging in evidence-based medicine
2. History and international developments in cancer staging
3. Staging prostate cancer - 1997: Current methods and limitations
4. Diagnosis and staging of prostate cancer
5. Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer
6. Radical prostatectomy. Patterns of local failure and survival in 67 patients
7. The risk of dying of prostate cancer in patients with clinically localized disease
8. Clinical progression of breast cancer malignant behavior: What to expect and when to expect it
9. Nerve-sparing radical prostatectomy: Extraprostatic tumor extension and preservation of erectile function
10. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team
11. Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate
12. Separating favorable from unfavorable prognostic markers in breast cancer: The role of E-cadherin
13. The pathogenesis of cancer metastasis
14. Molecular basis of tumour metastasis
15. What defines a useful marker of metastasis in human cancer?
16. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate
17. The relationship between nm23, angiogenesis, and the metastatic proclivity of node-negative breast cancer
18. The metastatic process: Basic research and clinical implications
19. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer
20. Development of markers of prostate cancer metastasis: Review and perspective
21. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival
22. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer
23. Isolation and characterization of a gene specifically expressed in different metastatic cells and whose deduced gene product has a high degree of homology to a Ca2+-binding protein family
24. Differential expression of a novel gene, WDNM1, in nonmetastatic rat mammary adenocarcinoma cells
25. Transcriptional down-regulation of a rat gene, WDNM2, in metastatic DMBA-8 cells
26. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas
27. Extracellular matrix regulation of cell-cell communication and tissue-specific gene expression in primary liver cultures
28. Search for genes that suppress cancer metastasis
29. Genetic control of cancer metastasis
30. Evidence for a novel gene associated with low tumor metastatic potential
31. KAI1, a putative marker for metastatic potential in human breast cancer
32. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss
33. Angiogenesis and angiogenesis inhibition: An overview
34. The role of angiogenesis in tumor growth
35. Organ targeting in vivo using phage display peptide libraries
36. Review: Biologic heterogeneity of cancer metastases
37. Critical factors in the biology of human cancer metastasis: Twenty- eighth G.H.A. Clowes memorial award lecture
38. Intravascular origin of metastasis from the proliferation of endotheliumattached tumor cells: A new model for metastasis
39. Clinical targets for anti-metastasis therapy
40. A fluorescent orthotopic bone metastasis model of human prostate cancer
41. Steps in tumor metastasis: New concepts from intravital videomicroscopy
42. In vivo videomicroscopy of experimental hematogenous metastasis: Cancer cell arrest, extravasation and migration
43. Regulation of tumor cell growth at organ-specific metastases
44. Critical determinants of melanoma metastasis
45. E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway
46. E-cadherin downregulation in cancer: Fuel on the fire?
47. Integrin signaling
48. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
49. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
50. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry
51. Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential
52. Cell fusion segregates progressive growth from metastasis
53. The use of cell fusion to analyse factors involved in tumour cell metastasis
54. Selective suppression of metastasis but not tumorigenicity of a mouse lung carcinoma by cell hybridization
55. Genetic suppression of tumor formation
56. The analysis of malignancy by cell fusion: The position in 1988
57. Genetic factors and suppression of metastatic ability of prostatic cancer
58. Microcell-mediated transfer of murine chromosomes into mouse, Chinese hamster, and human somatic cells
59. Preparation of microcells
60. Lessons learned from studies on tumor suppression by microcell-mediated chromosome transfer
61. Selective transfer of individual human chromosomes to recipient cells
62. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells
63. Localization of prostate cancer metastasis-suppressor activity on human chromosome 17
64. Identification of a novel metastasis-suppressor region on human chromosome 12
65. Regulatory mechanisms of replication growth limits in cellular senescence
66. Evidence for two senescence loci on human chromosome 1
67. Decrease in amplified telomeric sequences and induction of senescence markers by introduction of human chromosome 7 or its segments in SUSM-1
68. Human chromosome 7 carries a putative tumor suppressor gene(s) involved in choriocarcinoma
69. Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosomal region 17q
70. Suppression of tumorigenicity of human prostate cancer cells by introduction of human chromosome del(12)(q13)
71. Nuclear-cytoskeletal interactions: Evidence for physical connections between the nucleus and cell periphery and their alteration by transformation
72. Metastasis suppressed, but tumorigenicity and local invasiveness unaffected, in the human melanoma cell line MelJuSo after introduction of human chromosomes 1 or 6
73. Suppression of human melanoma metastasis by introduction of chromosome 6 may be partially due to inhibition of motility, but not to inhibition of invasion
74. Suppression of human melanoma metastasis following introduction of chromosome 6 is independent of NME1 (Nm23)
75. Suppression of MDA-MB-435 breast carcinoma cell metastasis following the introduction of human chromosome 11
76. Metastasis suppressor gene(s) for rat prostate cancer on the long arm of human chromosome 7
77. Mapping of metastasis suppressor gene(s) for rat prostate cancer on the short arm of human chromosome 8 by irradiated microcell-mediated chromosome transfer
78. Suppression of invasive ability of highly metastatic rat prostate cancer by introduction of human chromosome 8
79. Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10
80. Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11
81. Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11
82. Human chromosome 16 suppresses metastasis but not tumorigenesis in rat prostatic tumor cells
83. Chromosomal localization and nucleoside diphosphate kinase activity of human metastasis-suppressor genes NM23-1 and NM23-2
84. Inhibition of cell motility after nm23 transfection of human and murine tumor cells
85. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells
86. Effects of cytokine-mediated modulation of nm23 expression on the invasion and metastatic behavior of B16F10 melanoma cells
87. Nm23/nucleoside diphosphate kinase: Toward a structural and biochemical understanding of its biological functions
88. Two isotypes of murine nm23/nucleoside diphosphate kinase, nm23-M1 and nm23-M2, are involved in metastatic suppression of a murine melanoma line
89. Identification of highly expressed genes in metastasis-suppressed chromosome 6/human malignant melanoma hybrid cells using subtractive hybridization and differential display
90. Differential gene expression in tumor metastasis: Nm23
91. Nm23 and tumour metastasis: Basic and translational advances
92. Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: Effects on tumor metastatic potential, colonization and enzymatic activity
93. Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: A 31P nuclear magnetic resonance study in vivo and in vitro
94. nm23 - Relationship to the metastatic potential of breast carcinoma cell lines, primary human xenografts, and lymph node negative breast carcinoma patients
95. Decreased expression of nucleoside diphosphate kinase alpha isoform, an nm23-H2 gene homolog, is associated with metastatic potential of rat mammary-adenocarcinoma cells
96. Inhibition of colonization and cell-matrix adhesion after nm23-H1 transfection of human prostate carcinoma cells
97. The role of nm23 in transforming growth factor beta 1-mediated adherence and growth arrest
98. Overexpression of nm23-H2/NDP kinase B in a human oral squamous cell carcinoma cell line results in reduced metastasis, differentiated phenotype in the metastatic site, and growth factor-independent proliferative activity in culture
99. Immunohistochemical analysis of nucleoside diphosphate kinases in oral squamous cell carcinomas
100. Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer
101. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2
102. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13
103. Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer
104. CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins
105. Characterization of integrin-tetraspanin adhesion complexes: Role of tetraspanins in integrin signaling
106. The tetraspanin superfamily: Molecular facilitators
107. Correlation between reduction of metastasis in the MDA-MB-435 model system and increased expression of the Kai-1 protein
108. Analysis of KAI-1 mRNA expression in human breast cancer cell lines
109. Reduced invasive and metastatic potentials of KAI1-transfected melanoma cells
110. Suppression of invasive properties of colon cancer cells by a metastasis suppressor KAI1 gene
111. Loss of KAI1 expression in the progression of colorectal cancer
112. Chromosome localization and genomic structure of the KiSS-1 metastasis suppressor gene (KISS1)
113. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene
114. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KISS-1
115. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13
116. The gene encoding protein kinase SEK1 maps to mouse chromosome 11 and human chromosome 17
117. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17
118. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways
119. Signal transduction by the c-Jun N-terminal kinase (JNK) - From inflammation to development
120. Are CD44 variant isoforms involved in human tumour progression?
121. Methylation of the CD44 metastasis suppressor gene in human prostate cancer
122. Decreased expression of CD44 in metastatic prostate cancer
123. Altered expression of CD44 in human prostate cancer during progression
124. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: Relation to Gleason grade and cytoarchitecture
125. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy
126. Correlation of p34cdc2 cyclin-dependent kinase over-expression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas
127. The normal structure and function of CD44 and its role in neoplasia
128. A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene
129. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells
130. Maspin suppresses the invasive phenotype of human breast carcinoma
131. Rat and human maspins: Structures, metastatic suppressor activity and mutation in prostate cancer cells
132. Cancer as a disease of DNA organization and dynamic cell structure
133. KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases
134. KAI1, a new metastasis suppressor gene, is reduced in metastatic hepatocellular carcinoma
135. Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers
136. Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer
137. Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma
138. Frequent loss of KAI1 expression in squamous and lymphoid neoplasms. An immunohistochemical study of archival tissues
139. Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases
140. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
141. Molecular mechanisms controlling human melanoma progression and metastasis
142. Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumori-genicity
143. A human melanoma metastasis-suppressor locus maps to 6q16.3-q23
144. Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate
145. An expressed-sequence-tag database of the human prostate: Sequence analysis of 1168 cDNA clones
146. PEDB: The Prostate Expression Database
147. Tissue structure, nuclear organization, and gene expression in normal and malignant breast
148. Extracellular matrix signaling: Integration of form and function in normal and malignant cells
149. Genetic and epigenetic influences in prostatic carcinogenesis
150. Epithelial-mesenchymal interactions in the bladder. Implications for bladder augmentation
151. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium
152. Prostate epithelial differentiation is dictated by its surrounding stroma
153. The role of stromal-epithelial interaction in normal and malignant growth
154. Implications of stromal-epithelial interaction in human prostate cancer growth, progression and differentiation
155. Technical considerations for studying cancer metastasis in vivo
156. Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor/E2F pathway
157. Self-organization, complexity and chaos: The new biology for medicine
158. Explaining aberrations of cell structure and cell signaling in cancer using complex adaptive systems